ALAArovella TherapeuticsALA info
$0.11info9.09%24h
Global rank
Market cap$102.80M
Change 7d-
YTD Performance50.00%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Arovella Therapeutics (ALA) Stock Overview

    Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

    ALA Stock Information

    Symbol
    ALA
    Address
    Corporate OncePreston, VIC 3072Australia
    Founded
    -
    Trading hours
    10:00 AM - 4:00 PM AEST
    Website
    https://www.arovella.com
    Country
    πŸ‡¦πŸ‡Ί Australia
    Phone Number
    61 3 9863 6472

    Arovella Therapeutics (ALA) Price Chart

    -
    Value:-

    Arovella Therapeutics Overview: Key Details and Summary

    Stock data
    2025
    Change
    Price
    $0.11210133961100835
    N/A
    Market Cap
    $102.80M
    N/A
    Shares Outstanding
    917.04M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org